Literature DB >> 6985722

Valproic acid and plasma levels of phenobarbital.

J Bruni, B J Wilder, R J Perchalski, E J Hammond, H J Villarreal.   

Abstract

During concurrent administration of phenobarbital and valproic acid, phenobarbital plasma concentrations often increase. This often requires a reduction of phenobarbital dosage. In normal cats and patients with epilepsy, we found no evidence of decreased renal excretion of phenobarbital. Metabolic studies in four patients revealed a decrease in the conversion of phenobarbital to hydroxyphenylphenobarbital and decreased urinary ratios of hydroxyphenylphenobarbital to phenobarbital. These data suggest that phenobarbital metabolism is inhibited by therapeutic plasma levels of valproic acid.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6985722     DOI: 10.1212/wnl.30.1.94

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  Influence of chronic barbiturate administration on sleep apnea after hypersomnia presentation: case study.

Authors:  J Takhar; J Bishop
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

3.  A method for chronic intravenous catheterization in the cat.

Authors:  S M Cochrane; J M Parent; D G Allen; W D Black; A E Valliant; J H Lumsden
Journal:  Can Vet J       Date:  1989-05       Impact factor: 1.008

Review 4.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

5.  An epidemiological study of the clinical impact of pharmacokinetic anticonvulsant drug interactions based on serum drug level analysis.

Authors:  F Pisani; A Fazio; C Artesi; G Oteri; B Pisani; F Romano; E Perucca; R Di Perri
Journal:  Ital J Neurol Sci       Date:  1987-04

Review 6.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

9.  Inhibition of phenobarbitone N-glucosidation by valproate.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 10.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.